Sanofi is reorganizing her immuno-oncology collaboration with Regeneron. Regeneron Libtayo will receive exclusive license rights, subject to the terms of the new, modified and restored cooperation and license agreement. Sanofi Libtayo will receive $ 900 million in advance payments and 11% royalties for worldwide net sales, as well as $ 100 million in regulatory milestone payments as well as eligibility for milestone payments on sales links. Which could reach মিল 100 million in the next two years.
The Global Immuno-Oncology Cooperation and Licensing Agreement between Sanofi and Regeneron expired in 2015. So far, the two companies have shared operating profits from global Libtayo sales, and jointly marketed the product in the United States – Sanofi is solely responsible for marketing it elsewhere in the world.
Bill Seabold, Executive Vice President, Specialty Care and President, North America, Sanofi: “Our diversified oncology portfolio has doubled in size between 2019 and 2022 and now consists of twelve molecules in clinical trials, each with a unique process-immuno-immune. The first steps we have taken have made it possible to lay a solid foundation for the renewal of the initiatives we are taking in the field of oncology. We will work closely with Regeneron in our immunology to ensure that the transfer of Libtayo-related rights is in the best possible condition without affecting patients.
In accordance with the amended and restored cooperation and licensing agreement, Sanofi will transfer the rights to develop, commercialize and manufacture Libtayo worldwide to Regeneron for a specified period of time (which will begin when all necessary regulatory approvals are obtained). In return, Sanofi will receive 900 900 million in advance payments and 11% royalties on Libtayo’s global net sales. Sanofi will also be eligible for a 100 100 million regulatory milestone payment – which is expected to occur after Libtayoke is approved by the Food and Drug Administration (FDA) or the European Commission for first-line treatment of certain categories of patients. Non-Small Cell Lung Cancer (NSCLC), a combination of chemotherapy – as well as milestone payments for the sale of this product that could reach a total of $ 100 million over the next two years. The termination of this transaction will be subject to the approval of the competition authorities and should be finalized by the third quarter of 2022.
Regeneron will also accelerate the repayment of the balance of development costs related to the separate “antibody” cooperation between the two companies. Regeneron will increase its share of the profits returned to Sanofi by 10% to 20% in return for the development costs financed by Sanofi until a portion of the total growing development expenditure is absorbed by this remaining collaboration.
Sanofi continues to strengthen its vast knowledge in oncology and expands its research and development capabilities to focus on hard-to-treat cancers such as breast, blood and lung cancers. The company is committed to transforming scientific discoveries into potential new treatments and filling important gaps in cancer care.
Source and Visual: Sanofi